Testosterone supplementation did not show consistent benefit for cardiovascular risk , sexual function , mood and behavior , or cognition .
Studies that examined clinical cardiovascular endpoints have not favored testosterone therapy over placebo .
Testosterone is ineffective in treating erectile dysfunction and controlled trials did not show a consistent effect on libido .
Testosterone supplementation consistently increased muscle strength but did not have beneficial effects on physical function .
Most studies on mood-related endpoints found no beneficial effect of testosterone treatment on personality , psychological well-being , or mood .
Testosterone products are recommended by some prescribers in response to a diagnosis or presumption of " low testosterone " ( low-T ) for cardiovascular health , sexual function , muscle weakness or wasting , mood and behavior , and cognition .
Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina.
OBJECTIVE In women , sex hormones cause increased morbidity and mortality in patients with coronary heart disease ( CHD ) and adversely affect the coagulation profile . We have studied the effect of physiological testosterone replacement therapy in men on coagulation factor expression , to determine if there is an increased risk of thrombosis . METHODS Double-blind , r and omized , placebo-controlled trial of testosterone in 46 men with chronic stable angina . Measurements of free , total and bioavailable testosterone , luteinising hormone ( LH ) and follicle-stimulating hormone ( FSH ) , estradiol , plasminogen activator inhibitor-1 ( PAI-1 ) , fibrinogen , tissue plasminogen activator ( tPA ) and full blood count were made at 0 , 6 and 14 weeks . RESULTS Bioavailable testosterone levels were : 2.58 + /- 0.58 nmol/l at baseline , compared with 3.35 + /- 0.31 nmol/l at week 14 ( P < 0.001 ) after treatment compared with 2.6 + /- 0.18 nmol/l and 2.44 + /- 0.18 nmol/l in the placebo group ( P was not significant ) . There was no change in fibrinogen ( 3.03 + /- 0.18 g/l at baseline and 3.02 + /- 0.18 g/l at week 14 , P = 0.24 ) , tPA activity ( 26.77 + /- 4.9 Iu/ml and 25.67 + /- 4.4 Iu/ml , P = 0.88 ) or PAI-1 activity ( 0.49 + /- 0.85 Iu/ml and 0.36 + /- 0.06 Iu/ml , P = 0.16 ) with active treatment and no differences between the groups ( at week 14 , P value 0.98 , 0.59 and 0.8 for fibrinogen , PAI-1 and tPA respectively ) . Haemoglobin concentration did not change over time , in the testosterone group ( 1.44 + /- 0.02 g/l and 1.45 + /- 0.02 g/l , P = 0.22 ) . CONCLUSION Physiological testosterone replacement does not adversely affect blood coagulation status
Testosterone supplementation did not show consistent benefit for cardiovascular risk , sexual function , mood and behavior , or cognition .
Studies that examined clinical cardiovascular endpoints have not favored testosterone therapy over placebo .
Testosterone is ineffective in treating erectile dysfunction and controlled trials did not show a consistent effect on libido .
Testosterone supplementation consistently increased muscle strength but did not have beneficial effects on physical function .
Most studies on mood-related endpoints found no beneficial effect of testosterone treatment on personality , psychological well-being , or mood .
Testosterone products are recommended by some prescribers in response to a diagnosis or presumption of " low testosterone " ( low-T ) for cardiovascular health , sexual function , muscle weakness or wasting , mood and behavior , and cognition .